China Resources Pharmaceutical Group Ltd
HKEX:3320
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
4.51
6.99
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
China Resources Pharmaceutical Group Ltd
Total Equity
China Resources Pharmaceutical Group Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
Total Equity
HK$48.4B
|
CAGR 3-Years
0%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
G
|
Grand Pharmaceutical Group Ltd
HKEX:512
|
Total Equity
HK$15.7B
|
CAGR 3-Years
9%
|
CAGR 5-Years
15%
|
CAGR 10-Years
33%
|
|
|
S
|
SSY Group Ltd
HKEX:2005
|
Total Equity
HK$7.3B
|
CAGR 3-Years
7%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
|
U
|
United Laboratories International Holdings Ltd
HKEX:3933
|
Total Equity
¥13.5B
|
CAGR 3-Years
14%
|
CAGR 5-Years
16%
|
CAGR 10-Years
9%
|
|
|
Sino Biopharmaceutical Ltd
HKEX:1177
|
Total Equity
¥32.8B
|
CAGR 3-Years
10%
|
CAGR 5-Years
2%
|
CAGR 10-Years
22%
|
|
|
H
|
HUTCHMED (China) Ltd
HKEX:13
|
Total Equity
$740.1m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
16%
|
CAGR 10-Years
23%
|
|
China Resources Pharmaceutical Group Ltd
Glance View
China Resources Pharmaceutical Group Ltd. is an investment holding, which engages in the research and development, manufacture, distribution, and retail of pharmaceutical and healthcare products. The Company, along with its subsidiaries, is principally engaged in the research and development, manufacturing, distribution and retail of pharmaceutical and other healthcare products. The firm mainly operates through three segments. Pharmaceutical Manufacturing segment is engaged in the research and development, manufacturing and sale of pharmaceutical and other healthcare products. Pharmaceutical Distribution segment is engaged in the provision of distribution solutions to pharmaceutical manufacturers and dispensers, such as hospitals and other medical institutions, distributors and retail pharmacies. Pharmaceutical Retail segment is involved in the operation of retail pharmacies in China and Hongkong.
See Also
What is China Resources Pharmaceutical Group Ltd's Total Equity?
Total Equity
48.4B
HKD
Based on the financial report for Jun 30, 2024, China Resources Pharmaceutical Group Ltd's Total Equity amounts to 48.4B HKD.
What is China Resources Pharmaceutical Group Ltd's Total Equity growth rate?
Total Equity CAGR 5Y
3%
Over the last year, the Total Equity growth was 6%.
You don't have any saved screeners yet
